INVASIVE BREAST CARCINOMA

This phase III trial tests whether adding pembrolizumab (Keytruda) after standard chemotherapy can help prevent triple-negative breast cancer from coming back. Over 1,100 patients with residual cancer after chemo are randomly assigned to receive pembrolizumab or placebo. The stud…

This large phase 3 trial studied over 5,000 women with hormone receptor-positive, HER2-negative breast cancer that had spread to 1-3 lymph nodes. Participants received standard hormone therapy (tamoxifen or an aromatase inhibitor) either alone or with chemotherapy. The goal was t…

This study tests whether giving two immunotherapy drugs (decitabine and pembrolizumab) before standard chemotherapy can help the immune system attack HER2-negative breast cancer more effectively. About 46 adults with locally advanced disease will receive a short course of these d…

This study is for people with HER2-positive stage II to IIIa breast cancer whose tumors completely disappear after initial chemotherapy and targeted therapy before surgery. The goal is to see if using fewer chemotherapy drugs after surgery can still keep the cancer from coming ba…

This study tests a shorter course of radiation (hypofractionated) to the breast and nearby lymph nodes in 137 women with node-positive breast cancer. The goal is to see if this approach reduces arm swelling (lymphedema) and other side effects while still preventing cancer from co…

This phase III trial tests whether adding tucatinib to standard T-DM1 therapy works better than T-DM1 alone at preventing breast cancer from coming back. It involves over 1,000 patients with HER2-positive breast cancer who still have cancer cells after initial treatment. The stud…

This study tests whether platinum-based chemotherapy (cisplatin or carboplatin) works better than capecitabine in people with a certain type of triple-negative breast cancer that remains after initial chemotherapy and surgery. About 415 participants with stage II-III breast cance…

This phase 2 trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy (carboplatin and paclitaxel) before surgery helps shrink tumors in people with stage II-III triple negative breast cancer. About 67 participants will receive either chemo alone or…

This study tests whether the drug ixabepilone can help people with HER2-negative breast cancer who still have significant cancer after standard chemotherapy. About 116 participants will either receive ixabepilone or standard care. The goal is to see if ixabepilone improves outcom…

This study tests a combination of targeted drugs (ribociclib, tucatinib, trastuzumab, with or without fulvestrant) for HER2-positive breast cancer. In the first part, it looks at safety in patients whose cancer has spread. In the second part, it compares these drugs to standard c…

This phase II trial tests a drug called sacituzumab govitecan in 44 patients with HER2-negative breast cancer that has spread to the brain. The drug is a targeted antibody that delivers chemotherapy directly to cancer cells. The goal is to see if it can shrink brain tumors or slo…

This phase II trial is testing a type of radiation called proton beam therapy for women with early-stage breast cancer (stage 0 to II). The goal is to see if this targeted approach can kill cancer cells while causing less damage to normal tissue, leading to fewer side effects and…

This phase 2 trial tests whether combining immunotherapy (avelumab) with other drugs can shrink tumors in people with advanced triple-negative breast cancer that has spread or come back. About 145 participants will receive one of several drug combinations, including avelumab plus…

This study tests whether adding the drug panitumumab to standard chemotherapy helps shrink tumors more effectively in people with a rare and aggressive type of breast cancer called triple-negative inflammatory breast cancer. About 42 participants will receive chemotherapy before …

This phase 1 trial is testing the safety and best dose of a combination of three drugs—entinostat, nivolumab, and ipilimumab—in people with advanced solid tumors that have spread or cannot be removed. The goal is to see if this mix can help the immune system fight cancer more eff…

This study looks at a way to help women under 40 with breast cancer keep their ability to have children after chemotherapy. Before starting chemo, participants receive hormone injections and tamoxifen to stimulate their ovaries, then eggs or embryos are frozen. The goal is to see…

This study tests a shorter, more focused radiation treatment (hypofractionated partial breast irradiation) for women with early-stage breast cancer. The goal is to see if targeting only the tumor site can reduce side effects and improve cosmetic outcomes compared to standard whol…

This phase II trial studies whether giving radiation therapy before surgery can shrink hormone receptor-positive, HER2-negative breast tumors. About 25 participants will receive radiation followed by breast surgery. The goal is to see if this approach reduces the amount of normal…

This phase III trial tests whether a shorter course of radiation (hypofractionated) after mastectomy can prevent cancer recurrence with fewer side effects than standard radiation. About 900 patients with stage II-IIIa breast cancer are participating. The study compares complicati…

This study tests whether giving an extra dose of radiation (a boost) before breast cancer surgery is safe and helpful. About 103 people with early-stage breast cancer that hasn't spread will receive the boost, then standard radiation and surgery. The goal is to see if this approa…

This phase IIb trial is testing whether combining a nightly fast (time-restricted eating) with the diabetes drug metformin can slow the growth of breast cancer cells before surgery. The study includes 120 women with early-stage breast cancer or a precancerous condition called DCI…

This study tests a high-dose, precise radiation therapy called SBRT for people with breast cancer who cannot undergo surgery. Fifteen participants will receive five radiation treatments and be followed for five years to check for side effects and tumor response. The goal is to se…

This phase 2 trial tests whether a special PET/CT scan using a radioactive tracer (FDG) can predict how well HER2-positive breast cancer responds to standard chemotherapy before surgery. About 235 patients with stage II-III HER2+ breast cancer will get the scan early in treatment…

This study tests whether a shorter course of higher-dose radiation (hypofractionated) is as good as or better than standard radiation for early-stage breast cancer. About 300 women with ductal carcinoma in situ or early invasive breast cancer are participating. The main goal is t…

This study compares two creams, Aquaphor and Miaderm, to see which one better treats skin irritation caused by radiation therapy in breast cancer patients. About 208 women with early-stage breast cancer will use one of the creams during their radiation treatment. The goal is to f…

This study compares a 3-week course of radiation to the standard 5-week course for breast cancer patients who need radiation to the lymph nodes. The goal is to see if the shorter schedule is just as effective at preventing cancer from coming back, while causing less arm swelling …

This study tests whether text message reminders and phone counseling help women with early-stage breast cancer take their daily hormone therapy pills as prescribed. About 1,167 women will be split into groups: some get usual care, others get texts and/or motivational interviewing…

This study collects blood and tissue samples from 300 people with breast cancer that has spread or come back. The goal is to create a large research registry that helps doctors understand why tumors spread and why people respond differently to treatments. Participants provide sam…

This study looks at whether certain genes make African American women with breast cancer more likely to develop nerve damage (pain, numbness, tingling) from common chemotherapy drugs called taxanes. About 249 women with stage I-III breast cancer will receive either docetaxel or w…

This study collects tissue and blood samples from 1,600 people with various advanced cancers, along with their medical information, over the course of their treatment. Researchers will store these samples and data in a biobank for current and future studies. The goal is to better…

This study looks at why women in the Hauts-de-France region of France may wait longer to start breast cancer treatment, even though they get cancer at similar rates as elsewhere. Researchers will track 500 women from their first symptom to their first treatment, breaking down del…

This study planned to give high doses of vitamin D to women with breast cancer before their surgery. Researchers wanted to see if the vitamin would change certain markers in the cancer cells. However, the study was withdrawn before any participants were enrolled, so no results ar…

This study looks at whether a genetic test on tumor samples can predict how well HER2-negative breast cancer will respond to standard treatments like chemotherapy or hormone therapy. About 1,100 people with stage I-III breast cancer are taking part. The goal is to see if this tes…

This study looks at how chemotherapy given before surgery affects the immune system in people with operable breast cancer. Researchers will collect blood samples to see if certain immune cells can predict how well the tumor responds to treatment. The goal is to better understand …

This study looks at whether women with small breast cancers (under 5 cm) and no signs of cancer in their lymph nodes on ultrasound can safely skip sentinel lymph node biopsy during breast-conserving surgery. About 1,734 women are being randomly assigned to either have the biopsy …

This study looks at how well a medicated gel (afimoxifene) is absorbed through the skin of the breast in women who have had radiation for breast cancer. Researchers want to understand if differences in skin type or past radiation change how much gel gets into the breast tissue. T…

This study planned to test whether MRI-guided focused ultrasound could destroy breast tumors before mastectomy. The procedure was to be done under local anesthesia and sedation. However, the trial was withdrawn before enrolling any participants, so no results are available.